Phase I Dose-Escalation Study of Onartuzumab as a Single Agent and in Combination With Bevacizumab in Patients With Advanced Solid Malignancies

Clinical Cancer Research - United States
doi 10.1158/1078-0432.ccr-13-2070
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Association for Cancer Research (AACR)

Related search

Phase 1 Dose-Escalation Study of Single-Agent Veliparib in Japanese Patients With Advanced Solid Tumors

Cancer Science
Cancer ResearchMedicineOncology
2017English

A Phase I Dose-Escalation Study of Selumetinib in Combination With Docetaxel or Dacarbazine in Patients With Advanced Solid Tumors

BMC Cancer
Cancer ResearchOncologyGenetics
2017English

A Phase 1, Open-Label, Dose Escalation Study of Intravenous Paricalcitol in Combination With Gemcitabine in Patients With Advanced Malignancies

Cancer
Cancer ResearchOncology
2018English

Erratum To: A Phase I Dose-Escalation Study of Selumetinib in Combination With Erlotinib or Temsirolimus in Patients With Advanced Solid Tumors

Investigational New Drugs
OncologyPharmacology
2017English

A Phase I Dose‐Escalation Study of the Safety and Pharmacokinetics of Pictilisib in Combination With Erlotinib in Patients With Advanced Solid Tumors

Oncologist
Cancer ResearchMedicineOncology
2017English

A First-In-Human, Phase I, Dose-Escalation Study of TAK-117, a Selective PI3Kα Isoform Inhibitor, in Patients With Advanced Solid Malignancies

Clinical Cancer Research
Cancer ResearchOncology
2017English

Phase I Dose-Escalation Study and Biomarker Analysis of E7080 in Patients With Advanced Solid Tumors

Clinical Cancer Research
Cancer ResearchOncology
2011English

Phase I Trial of FOLFIRI in Combination With Sorafenib and Bevacizumab in Patients With Advanced Gastrointestinal Malignancies.

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2014English

Phase I Dose-Escalation Study of Linsitinib (OSI-906) and Erlotinib in Patients With Advanced Solid Tumors

Clinical Cancer Research
Cancer ResearchOncology
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy